Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

ABBV-295

Stage Phase 2Stale

Sponsor AbbVie

Route oral and injection

Class Amylin

Mechanism long-acting amylin analog

Sources

registry, as of 2026-10-27Stale

https://clinicaltrials.gov/study/NCT07752979

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities. Overall status RECRUITING. Phases PHASE2. Lead sponsor AbbVie. Enrollment 360. Conditions Obesity; Overweight. Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing body weight at Week 32 in participants with obesit

ClinicalTrials.gov NCT07752979 protocol and results modules

registry, as of 2026-11-05

https://clinicaltrials.gov/study/NCT07291232

A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE1. Lead sponsor AbbVie. Enrollment 80. Conditions Obesity. This study is to assess adverse events, change in body weight and pharmacokinetics in adult participants with obesity receiving ABBV-295 subcutaneous injections or matching placebo.

ClinicalTrials.gov NCT07291232 protocol and results modules

registry, as of 2026-08-14Stale

https://clinicaltrials.gov/study/NCT07514260

A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE1. Lead sponsor AbbVie. Enrollment 24. Conditions Healthy Volunteer. The purpose of this study is to assess the adverse events, tolerability, and Pharmacokinetics (PK) of subcutaneous injections of ABBV-295 in healthy adult Japanese participants with overweight or obesity.

ClinicalTrials.gov NCT07514260 protocol and results modules

registry, as of 2026-08-31Stale

https://clinicaltrials.gov/study/NCT07414784

A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives. Overall status COMPLETED. Phases PHASE1. Lead sponsor AbbVie. Enrollment 20. Conditions Healthy Volunteer. This Study of ABBV-295 subcutaneous injections will assess pharmacokinetics and adverse events in healthy adult women participants with overweight or obesity taking oral contraceptives.

ClinicalTrials.gov NCT07414784 protocol and results modules

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT07752979

32 in participants with obesity or overweight with weight-related comorbidities. ABBV-295 is an investigational long-acting amylin analog being developed for chronic weight management. Participants are placed into multiple treatment groups with different dosing paradigms of ABBV-295 or placebo. Participants will not

NCT07752979 description or intervention text

Studies

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Registry NCT07752979

Phase Phase 2

Status Recruiting

Enrollment 360

Start 2026-08-04

ABBV-295 Arm 1

Comparator placebo

Population Obesity; Overweight

ABBV-295 Arm 2

Comparator placebo

Population Obesity; Overweight

ABBV-295 Arm 3

Comparator placebo

Population Obesity; Overweight

ABBV-295 Arm 4

Comparator placebo

Population Obesity; Overweight

ABBV-295 Arm 5

Comparator placebo

Population Obesity; Overweight

ABBV-295 Arm 6

Comparator placebo

Population Obesity; Overweight

Placebo

Population Obesity; Overweight

A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity

Registry NCT07291232

Phase Phase 1

Status Active, not recruiting

Enrollment 80

Start 2025-11-19

ABBV-295 or Placebo-Group 1

Population Obesity

ABBV-295 or Placebo-Group 2

Population Obesity

ABBV-295 or Placebo-Group 3

Population Obesity

ABBV-295 or Placebo-Group 3 Extension

Population Obesity

ABBV-295 or Placebo-Group 4

Population Obesity

ABBV-295 or Placebo-Group 4 Extension

Population Obesity

ABBV-295 or Placebo-Group 5

Population Obesity

ABBV-295 or Placebo-Group 6

Population Obesity

A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.

Registry NCT07514260

Phase Phase 1

Status Active, not recruiting

Enrollment 24

Start 2026-03-31

ABBV-295 Part 1

Comparator placebo

Population Healthy Volunteer

Placebo for ABBV-295 Part 1

Population Healthy Volunteer

ABBV-295 Part 2

Comparator placebo

Population Healthy Volunteer

Placebo for ABBV-295 Part 2

Population Healthy Volunteer

A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives

Registry NCT07414784

Phase Phase 1

Status Completed

Enrollment 20

Start 2026-02-11

Primary completion 2026-08-04

Study completion 2026-08-04

Catalyst Primary completion. 2026-08-04. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

ABBV-295 with Levonorgestrel and Ethinyl Estradiol

Population Healthy Volunteer